Evaluation of Viral-Specific T-Cell Therapy for Refractory Cytomegalovirus Infections in Adults Post-Allogeneic Hematopoietic Stem Cell Transplantation

The primary objective of this clinical trial is to evaluate the **safety** of viral-specific T-cell (VST) therapy in the treatment of **refractory viral infections** caused by **cytomegalovirus (CMV)** in adult patients following **allogeneic hematopoietic stem cell transplantation**. This is clinically relevant as CMV infections can lead to significant morbidity and mortality in this patient population, and current treatment options may be limited or ineffective. The study aims to determine the safety profile of VST therapy, which could potentially offer a novel therapeutic approach for managing these challenging infections.

The clinical trial involves adult participants who have undergone **allogeneic hematopoietic stem cell transplantation** and are experiencing resistant viral infections caused by **cytomegalovirus (CMV)**. The study population includes both male and female subjects, with an age range that encompasses young adults to older adults. The trial population is considered vulnerable due to their medical condition and treatment history. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet or physical activity. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The study aims to address a significant medical need in this specific patient group.

The clinical trial is designed as a **Phase 1**, multicenter, open-label, dose-escalation study aimed at evaluating the safety of viral-specific T-cell (VST) therapy in the treatment of resistant viral infections caused by **cytomegalovirus (CMV)** in adult patients following allogeneic hematopoietic stem cell transplantation. The trial is expected to commence recruitment on March 1, 2025, and is projected to conclude by December 31, 2026. Participants will be involved in the study for the duration necessary to complete the treatment and follow-up assessments, with the possibility of early termination if specific conditions arise, such as adverse reactions or withdrawal of consent.

The trial will involve a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo a baseline visit where initial assessments and measurements are conducted. Subsequent visits will be scheduled to monitor the safety and efficacy of the VST therapy, with adjustments to dosage as necessary based on the dose-escalation design. The end-of-study visit will mark the completion of the participant's involvement, during which final evaluations will be performed to gather comprehensive data on the therapy's safety profile.

Throughout the trial, participants will be closely monitored for any adverse events or complications related to the therapy. The study's open-label nature allows for direct observation of the treatment effects, while the dose-escalation approach aims to identify the optimal therapeutic dose. The trial's design does not include a control group, as the primary focus is on safety evaluation. Participants may be withdrawn from the study if they experience significant adverse effects, fail to comply with study procedures, or choose to withdraw their consent at any point during the trial.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is not included in the available data. The documentation lacks specifics on the product's authorization status, pharmaceutical form, and the origin of the active substances.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on March 1, 2025, with an estimated completion date of December 31, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a range of parameters such as **biomarker levels** or symptom improvement scores to gauge initial efficacy signals. These parameters are typically measured at various timepoints throughout the trial to monitor changes and trends. The data collected will be analyzed using appropriate statistical methods to determine any potential efficacy of the investigational product. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.